Protocols for BNCT of glioblastoma multiforme at Brookhaven: Practical considerations
In this report we discuss some issues considered in selecting initial protocols for boron neutron capture therapy (BNCT) of human glioblastoma multiforme. First the tolerance of normal tissues, especially the brain, to the radiation field. Radiation doses limits were based on results with human and animal exposures. Estimates of tumor control doses were based on the results of single-fraction photon therapy and single fraction BNCT both in humans and experimental animals. Of the two boron compounds (BSH and BPA), BPA was chosen since a FDA-sanctioned protocol for distribution in humans was in effect at the time the first BNCT protocols were written and therapy studies in experimental animals had shown it to be more effective than BSH.
- Research Organization:
- Brookhaven National Lab. (BNL), Upton, NY (United States)
- Sponsoring Organization:
- USDOE Office of Energy Research, Washington, DC (United States)
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 434948
- Report Number(s):
- BNL-63695; CONF-9609293-4; ON: DE97001919
- Resource Relation:
- Conference: 7. international symposium on neutron capture therapy for cancer, Zurich (Switzerland), 4-7 Sep 1996; Other Information: PBD: [1996]
- Country of Publication:
- United States
- Language:
- English
Similar Records
Boron Neutron Capture Therapy (BNCT) Dose Calculation using Geometrical Factors Spherical Interface for Glioblastoma Multiforme
A proposed protocol for clinical trials of boron neutron capture therapy in glioblastoma multiforme